NTLA 8-K 2026-11-05

Intellia Therapeutics, Inc. (NTLA) 8-K dated 2026-11-05 — accession 0001193125-26-448673.

Intellia Therapeutics, Inc. (NTLA) is a biotechnology company listed on US.

Intellia Therapeutics, Inc. filed a 8-K on 2026-11-05. Accession 0001193125-26-448673.

This 8-K covers: Results of operations (Item 2.02), Exhibits (Item 9.01). SEC EDGAR holds the official filing and its exhibits.

Latest reported NTLA revenue for 2025-12-31 was $67.7M. Net income was -$412.7M. Revenue was up 16.9% from 2024-12-31 to 2025-12-31. NTLA currently screens at market cap $1.19B.

Not investment advice. The NTLA SEC hub lists recent forms. The stock page is the research view.